CRM · Investment summary · as of 3 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
Size is the strategy's, set against its own position and exposure limits.
At $185.96, CRM requires a -5% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 9%.
The growth axis cannot be the disagreement: required growth is negative at both C1 windows and the price clears at the identity floor. At the 5th percentile of its own multiple history the market is disputing margin durability through the consumption-pricing transition on a levered balance sheet.
The conditions that would settle the disagreement are dated to September 2026.
The value rests on an exit multiple of 5.7x, a terminal operating margin of 24% and a 8.4% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Consumption-pricing transition compresses revenue per customer while the balance sheet is levered.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The growth axis cannot be the disagreement: required growth is negative at both C1 windows and the price clears at the identity floor. |
| What do we forecast? | Revenue growth of 9% demonstrated; a terminal operating margin of 24%; an exit multiple of 5.7x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is +10.3 percentage points. |
| What is it worth? | Twelve-month target $257.00, +38% from the struck price. Scenario-weighted expected return net of costs +26.7%. |
| Why now? | The first dated test of the thesis falls on 2 September 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 2 September 2026 | Organic YoY growth | Q2 FY27 organic revenue growth (reported less disclosed Informatica contribution) at or above 6.0% | Q2 FY27 organic revenue growth (reported less disclosed Informatica contribution) below 6.0% |
| every print through FY27 (Q1 FY27: +14%) | Current remaining performance obligation YoY | CRPO YoY growth at or above 10% in any quarter | cRPO YoY growth below 10% in any quarter |
| Q2 + Q3 FY27 | Sub-CoR growth minus sub-revenue growth | Subscription cost-of-revenue YoY growth exceeds subscription revenue YoY growth by no more than 5pp for two consecutive… | Subscription cost-of-revenue YoY growth exceeds subscription revenue YoY growth by more than 5pp for two consecutive… |
| Q3 FY27 print ~early Dec 2026 | Organic YoY growth, sequential comparison | Neither leg of the condition opposite is met at this date | Q3 FY27 organic growth does not exceed Q2 FY27 organic growth - management's self-set H2 organic-acceleration… |
Consumption-pricing transition compresses revenue per customer while the balance sheet is levered. Named mechanism: deliberate per-seat -> consumption migration (Agentic Work Units, token metering); every historical software pricing transition compressed revenue per customer first; CRM discloses no seats/price/NRR so compression surfaces only in cRPO, which Informatica masks until Q1 FY28; $39.3bn debt does not amortise, ~$2.0bn/yr interest against the EBIT base. Quantified: $80-100/share (identity-floor 10.6x EV/EBIT on stagnant ~$8.7bn EBIT, full net debt borne by equity), loss -46% to -57%, mid -50.3%. not a going-concern case: >7x interest cover on $15.2bn TTM OCF, argued explicitly.
Estimated probability 25%, against the 20% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
trim/exit when forward E[R] <= 0 net of costs - mechanically ~$292 on current NTM at the 1y-p90 multiple (5.36x), or ~$257 base target on unchanged estimates; recheck quarterly as NTM rolls On approach to the $257.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Consumption-pricing transition compresses revenue per customer while the balance sheet is levered. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +10.3 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: consumption-pricing transition compresses revenue per customer while the balance sheet is levered. The next evidence that should change the portfolio decision is the test dated 2 September 2026, or a daily close below $160.87, which forces an immediate review.